Alzchem Group AG: Investment program worth around EUR 120 million adopted for further capacity expansion in creatine products

Trostberg, December 4, 2025 – Alzchem Group AG has adopted a comprehensive investment program for further capacity expansion in creatine products. The focus is particularly on the areas of health, nutrition and pharmaceuticals. A total of around EUR 120 million is to be invested in the construction of a new, increasingly automated production facility for creatine and its precursors, as well as in the upstream infrastructure. Commissioning is planned in stages starting in the second half of 2027. Alzchem sees the investment as having additional annual sales potential in the early triple-digit million range with correspondingly positive earnings contributions.